Dietmar Berger, MD, PhD
Chief Medical Officer
2025 – Present
1 year (current)
Key Decisions & Impact
Appointed in early 2025, Dr. Dietmar Berger assumed control of Gilead's entire global clinical development and medical affairs operations. Inheriting a diversified clinical pipeline spanning virology, oncology, and inflammation, he immediately prioritized the acceleration of late-stage clinical trials for the company's most promising solid-tumor treatments. He also instituted rigorous new data-sharing protocols across the global R&D organization to improve the efficiency and speed of drug discovery.
Legacy
As Chief Medical Officer, Dr. Berger provides the essential scientific leadership required to translate Gilead's R&D budget into actual, approved therapeutics. His extensive background in oncology development is critical to ensuring the success of the company's recent, multi-billion dollar acquisitions, positioning Gilead to become a dominant player in the future of cancer treatment. His deep understanding of complex regulatory pathways and clinical trial design is essential to moving these novel therapies from the laboratory to the market as quickly and safely as possible, ensuring that patients receive access to potentially life-saving treatments.